Evotec SE

1EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,827

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,203.9028.800.35%
CAC 407,606.7570.490.94%
DAX 4022,379.55137.100.62%
Dow JONES (US)40,113.5020.100.05%
FTSE 1008,434.9619.710.23%
HKSE21,971.968.78-0.04%
NASDAQ17,382.94216.901.26%
Nikkei 22535,839.99134.250.38%
NZX 50 Index12,098.8981.050.67%
S&P 5005,525.210.000.00%
S&P/ASX 2007,997.1028.900.36%
SSE Composite Index3,288.416.65-0.20%

Market Movers